PCSK9 inhibition and clinical cardiovascular outcomes in patients with atherosclerotic cardiovascular disease

Cardiovasc Res. 2017 Jul 1;113(8):e24-e25. doi: 10.1093/cvr/cvx109.

Author

Ulf Landmesser¹

Affiliation

¹ Department of Cardiology, Berlin Institute of Health (BIH), German Center of Cardiovascular Research (DZHK), Charité-Universitätsmedizin Berlin, Berlin, Germany.

PMID: 28863442
DOI: 10.1093/cvr/cvx109

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cardiovascular Diseases*
Humans
Proprotein Convertase 9*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
PCSK9 protein, human
Proprotein Convertase 9
evolocumab